|
|||||
|
|
Circulating MiR-133a as a Biomarker Predicts Cardiac Hypertrophy in Chronic Hemodialysis Patients |
|
| Authors: | Ping Wen Dan Song Hong Ye Xiaochun Wu Lei Jiang Bing Tang Yang Zhou Li Fang Hongdi Cao Weichun He Yafang Yang Chunsun Dai Junwei Yang |
| Affiliation: | 1. Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.; 2. Department of Radiology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.; 3. Department of Nephrology, Affiliated Wuxi Hospital, Nanjing Medical University, Wuxi, China.; Loyola University Chicago, United States of America, |
| Abstract: | BackgroundMicroRNAs (miRNAs) are small ribonucleotides regulating gene expression. MicroRNAs are present in the blood in a remarkably stable form and have emerged as potential diagnostic markers in patients with cardiovascular disease. Our study aimed to assess circulating miR-133a levels in MHD patients and the relation of miR-133a to cardiac hypertrophy.MethodsWe profiled miRNAs using RNA isolated from the plasma of participants. The results were validated in 64 MHD patients and 18 healthy controls.ResultsLevels of plasma miR-133a decreased in MHD patients with LVH compared with those in healthy controls. Plasma miR-133a concentrations were negatively correlated with LVMI and IVS. After single hemodialytic treatment, plasma miR-133a levels remained unchanged. Cardiac Troponin I and T were not associated with LVMI and IVS.ConclusionsOur observations supplied the possibility that circulating miR-133a could be a surrogate biomarker of cardiac hypertrophy in MHD patients. |
| Keywords: | |